உயிர்வேதியியல் மற்றும் உடலியல் இதழ்

Zinc Reduces Fibrosis Scores in the Liver and Increases SVR to Triple and Dual DAA s Treatment in Chronic Hepatitis C Patients

Shimaa A Afify , Mohamed M Omran, Shimaa A Afify, Abdelfattah M Attallah, Muhamed M Abdel-Ghffar, Marwa A Abdel-Ghany, Sameh Saif, Azza Farid, Mohamad Hassany, Doaa Z Zaky, and Dalia Omran

The effect of Zinc (Zn) on liver fibrosis and Sustained Viral Response (SVR) of triple therapy (Sofosbuvir, pegylated interferon and ribavirin) and dual (Sofosbuvir and ribavirin) in chronic hepatitis C has not been established. This work aims to evaluate the therapeutic and antifibrotic effect of zinc on triple and dual therapy. Chronic hepatitis C (CHC) patients (N=300) were divided into 4 groups (G) with 75 patients each: G1: Received triple therapy for twelve weeks. G2: Received triple therapy plus oral zinc for twelve weeks. G3: Received dual therapy for twenty four weeks. G4: Received dual therapy plus oral zinc for twenty four weeks. The SVR was 93%, 96%, 83% and 92 % in G1, G2, G3 and G4; respectively. Triple therapy was more effective than dual therapy (p=0.03). The addition of zinc with dual therapy or triple therapy increased SVR than dual therapy without zinc (p=0.05 and p=0.008). Addition of zinc with dual therapy reduces the difference of SVR between G1 and G4 (p=0.772) and between G2 and G4 (p=0.33). The greatest antifibrotic effect was with triple therapy plus oral zinc (26%) the combination of zinc with triple treatment showed the best protection through their synergistic anti-fibrotic effect.